These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 23800433)

  • 1. IL-33 in rheumatoid arthritis: potential role in pathogenesis and therapy.
    Xu WD; Zhang M; Zhang YJ; Ye DQ
    Hum Immunol; 2013 Sep; 74(9):1057-60. PubMed ID: 23800433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL-32 with potential insights into rheumatoid arthritis.
    Xu WD; Zhang M; Feng CC; Yang XK; Pan HF; Ye DQ
    Clin Immunol; 2013 May; 147(2):89-94. PubMed ID: 23578550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel pro-inflammatory interleukins: potential therapeutic targets in rheumatoid arthritis.
    Bessis N; Boissier MC
    Joint Bone Spine; 2001 Dec; 68(6):477-81. PubMed ID: 11808983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-33: a promising therapeutic target for rheumatoid arthritis?
    Yuan FL; Li X; Lu WG; Li CW; Xu RS; Dong J
    Expert Opin Ther Targets; 2011 May; 15(5):529-34. PubMed ID: 21446881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-22 and rheumatoid arthritis: emerging role in pathogenesis and therapy.
    Xie Q; Huang C; Li J
    Autoimmunity; 2015 Mar; 48(2):69-72. PubMed ID: 25483133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting interleukin-21 in rheumatoid arthritis.
    Yuan FL; Hu W; Lu WG; Li X; Li JP; Xu RS; Li CW; Chen FH; Jin C
    Mol Biol Rep; 2011 Mar; 38(3):1717-21. PubMed ID: 20848219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic effects of interleukin-1β and interleukin-17A antibodies on collagen-induced arthritis mouse model.
    Zhang Y; Ren G; Guo M; Ye X; Zhao J; Xu L; Qi J; Kan F; Liu M; Li D
    Int Immunopharmacol; 2013 Feb; 15(2):199-205. PubMed ID: 23280345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutralizing IL-21 and IL-15 inhibits pro-inflammatory cytokine production in rheumatoid arthritis.
    Andersson AK; Feldmann M; Brennan FM
    Scand J Immunol; 2008 Jul; 68(1):103-11. PubMed ID: 18482208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of the Th17 cytokines IL-17 and IL-22 in Rheumatoid Arthritis pathogenesis and developments in cytokine immunotherapy.
    Roeleveld DM; Koenders MI
    Cytokine; 2015 Jul; 74(1):101-7. PubMed ID: 25466295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functions of interleukin-34 and its emerging association with rheumatoid arthritis.
    Zhou RP; Wu XS; Xie YY; Dai BB; Hu W; Ge JF; Chen FH
    Immunology; 2016 Dec; 149(4):362-373. PubMed ID: 27550090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic potential of IL-15 in rheumatoid arthritis.
    Yang XK; Xu WD; Leng RX; Liang Y; Liu YY; Fang XY; Feng CC; Li R; Cen H; Pan HF; Ye DQ
    Hum Immunol; 2015 Nov; 76(11):812-8. PubMed ID: 26429323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Th17 Cells in Immunopathogenesis and treatment of rheumatoid arthritis.
    Azizi G; Jadidi-Niaragh F; Mirshafiey A
    Int J Rheum Dis; 2013 Jun; 16(3):243-53. PubMed ID: 23981743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Broad Blockade of Signaling from the IL-20 Family of Cytokines Potently Attenuates Collagen-Induced Arthritis.
    Liu X; Zhou H; Huang X; Cui J; Long T; Xu Y; Liu H; Yu R; Zhao R; Luo G; Huang A; Liang JG; Liang P
    J Immunol; 2016 Oct; 197(8):3029-3037. PubMed ID: 27619991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-32, a proinflammatory cytokine in rheumatoid arthritis.
    Joosten LA; Netea MG; Kim SH; Yoon DY; Oppers-Walgreen B; Radstake TR; Barrera P; van de Loo FA; Dinarello CA; van den Berg WB
    Proc Natl Acad Sci U S A; 2006 Feb; 103(9):3298-303. PubMed ID: 16492735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.
    Joosten LA; Lubberts E; Helsen MM; Saxne T; Coenen-de Roo CJ; Heinegård D; van den Berg WB
    Arthritis Res; 1999; 1(1):81-91. PubMed ID: 11056663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role and therapeutic targeting of IL-6 in rheumatoid arthritis.
    Narazaki M; Tanaka T; Kishimoto T
    Expert Rev Clin Immunol; 2017 Jun; 13(6):535-551. PubMed ID: 28494214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selected cytokine pathways in rheumatoid arthritis.
    Noack M; Miossec P
    Semin Immunopathol; 2017 Jun; 39(4):365-383. PubMed ID: 28213794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis.
    Palmer G; Talabot-Ayer D; Lamacchia C; Toy D; Seemayer CA; Viatte S; Finckh A; Smith DE; Gabay C
    Arthritis Rheum; 2009 Mar; 60(3):738-49. PubMed ID: 19248109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Interleukins network in rheumatoid arthritis pathophysiology: beyond proinflammatory cytokines].
    Sánchez-Ramón S; López-Longo FJ; Carreño L
    Reumatol Clin; 2011 Mar; 6S3():S20-4. PubMed ID: 21794767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of interleukin-17 in mediating joint destruction in rheumatoid arthritis.
    Li X; Yuan FL; Lu WG; Zhao YQ; Li CW; Li JP; Xu RS
    Biochem Biophys Res Commun; 2010 Jun; 397(2):131-5. PubMed ID: 20513356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.